Niddafin (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, a key step in the synthesis of ergosterol, an essential component of the fungal cell membrane. Inhibiting this pathway leads to accumulation of toxic squalene and loss of membrane integrity, resulting in fungal cell death.

The dosage and frequency of Niddafin are determined by the prescribing healthcare professional based on the type and severity of the infection, the patient’s age, and the area of skin being treated. Patients should follow the prescriber’s instructions and the product label.

Safety data for topical terbinafine during pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Niddafin to pregnant or nursing individuals. Patients should discuss their situation with a qualified professional.

To request Niddafin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals, terbinafine has a different mechanism—blocking squalene epoxidase rather than lanosterol 14α‑demethylase. This often results in a faster fungicidal effect and may be preferred for certain dermatophyte infections, though choice depends on the specific pathogen, site of infection and patient factors.

Niddafin should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and efficacy.

Apply a thin layer of the cream or gel to the affected skin area once or twice daily, as directed by the prescriber. Gently rub it in until fully absorbed, and wash hands before and after application to avoid spreading the medication to other sites.

While most reactions are mild, serious adverse events can include allergic contact dermatitis, severe skin rash, urticaria, and, rarely, Stevens‑Johnson syndrome. Patients should discontinue use and seek medical attention if they notice extensive redness, blistering, swelling or systemic symptoms.

Individuals with a known hypersensitivity to terbinafine, other allylamine antifungals, or any component of the formulation should avoid Niddafin. It is also contraindicated on broken skin, mucous membranes, or in patients where a prescriber determines the risks outweigh the benefits.